Shopping Cart
Remove All
Your shopping cart is currently empty
8-Epideoxyloganic acid possesses bioactivities of analgesia, homeostasis and anti-inflammatory. It has the potential to serve as anti-inflammatory agents during oxidative stress, the inhibition of ROS production, possibly through modulation of NOX activity and/or the radical scavenging effect, and beta2 integrin expression in leucocytes. 8-Epideoxyloganic acid (oral) shows weak antinociceptive activity.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $83 | In Stock | In Stock | |
| 5 mg | $198 | In Stock | In Stock | |
| 10 mg | $292 | In Stock | In Stock | |
| 25 mg | $492 | In Stock | In Stock | |
| 50 mg | $717 | In Stock | In Stock | |
| 100 mg | $987 | In Stock | In Stock | |
| 500 mg | $1,980 | Backorder | Backorder | |
| 1 mL x 10 mM (in DMSO) | $530 | In Stock | In Stock |
| Description | 8-Epideoxyloganic acid possesses bioactivities of analgesia, homeostasis and anti-inflammatory. It has the potential to serve as anti-inflammatory agents during oxidative stress, the inhibition of ROS production, possibly through modulation of NOX activity and/or the radical scavenging effect, and beta2 integrin expression in leucocytes. 8-Epideoxyloganic acid (oral) shows weak antinociceptive activity. |
| In vivo | 8-Epideoxyloganic acid?exhibited anti-inflammatory activity. |
| Molecular Weight | 360.36 |
| Formula | C16H24O9 |
| Cas No. | 88668-99-9 |
| Smiles | [H][C@]12CC[C@@H](C)[C@@]1([H])[C@H](O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)OC=C2C(O)=O |
| Relative Density. | 1.52 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 22.5 mg/mL (62.44 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (2.78 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.